The role of recombinant insulin-like growth factor I in the treatment of the short child

Division of Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA.
Current Opinion in Pediatrics (Impact Factor: 2.74). 09/2007; 19(4):458-64. DOI: 10.1097/MOP.0b013e3282094126
Source: PubMed

ABSTRACT Commercial preparations of recombinant human insulin-like growth factor I became available in 2005. Off-label use has been promoted because of the paucity of patients having approved indications; I review the background and rationale for such use.
Attempts to identify growth hormone unresponsiveness in children with idiopathic short stature have been nonproductive. Treatment with insulin-like growth factor I for unequivocal growth hormone insensitivity improves but does not correct growth failure, in contrast to the typical experience with growth hormone replacement of growth hormone deficiency. This emphasizes the importance of direct effects of growth hormone at the growth plate, which cannot be duplicated by administration of recombinant insulin-like growth factor I. Adverse effects testify to the more than adequate delivery of administered recombinant human insulin-like growth factor I to other tissues, including lymphoid hyperplasia, coarsening of the facies, and increased body fat.
In view of the risk profile, the limited ability of endocrine insulin-like growth factor I to restore normal growth, and the suppression of endogenous growth hormone (and therefore local effects on growth) that occurs with insulin-like growth factor I administration, the use of recombinant insulin-like growth factor I should be limited to those with well-documented growth hormone unresponsiveness and severe short stature.

Download full-text


Available from: Arlan Rosenbloom, Sep 09, 2014
  • Source
    • "Let us consider recombinant IGF-1 therapy. The number of individuals with bonafide growth hormone resistance, the United States Food and Drug Administration (FDA) approved indication [1], is very small [2] [3]. FDA approval of recombinant IGF-1 was based on an experience of about 100 patients [1]. "
    International Journal of Pediatric Endocrinology 03/2009; 2009:303509. DOI:10.1155/2009/303509
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mecasermin [rDNA] (Increlex; Tercica, Inc.) is recombinant insulin-like growth factor-I (IGF-I) that has been approved to treat growth failure in children with severe primary IGF-I deficiency. Serious allergic reactions related to Increlex therapy have not been reported. We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.
    Journal of pediatric endocrinology & metabolism: JPEM 05/2008; 21(4):381-4. DOI:10.1515/JPEM.2008.21.4.381 · 0.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Idiopathic short stature is defined by height below 3rd percentile, in a child with normal birth height and weight, lack of dysmorphy, endocrine deficiency or systemic disease. Food and Drugs administration approved GH treatment in this indication in the United States, because it induces height gain, and sometimes may increase quality of life. There is no consensus in terms of duration, monitoring parameters, benefits and risks of long term GH treatment in these patients. Cost effectiveness of such a treatment is under debate, and ethical considerations also have to be taken into account. Recombinant IGF1 should not be proposed in this indication at the moment, due to the lack of sufficient data on potential GH insensitivity in a subgroup of these patients.
    Annales d Endocrinologie 09/2008; 69. DOI:10.1016/S0003-4266(08)73963-5 · 0.66 Impact Factor
Show more